![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Schrattenholz, EF Pereira, U Roth, KH Weber, EX Albuquerque and A Maelicke
Laboratory of Molecular Neurobiology, Johannes-Gutenberg University Medical School, Mainz, Germany.
Similar to the gamma-aminobutyric acidA receptor and the N-methyl-D- aspartate subtype of glutamate receptor, neuronal nicotinic acetylcholine receptors are subject to positive modulatory control by allosterically acting ligands. Exogenous ligands such as galanthamine and the neurotransmitter 5-hydroxytryptamine, when applied in submicromolar concentrations with nicotinic agonists, significantly increase the frequency of opening of nicotinic receptor channels and potentiate agonist-activated currents. Because these effects have been shown to be blocked by the monoclonal antibody FK1, they are mediated by binding sites that are located on alpha subunits of nicotinic receptors and distinct from those for acetylcholine and acetylcholine- competitive ligands. At higher concentrations, the potentiating effect of these ligands decreases and is eventually overcome by an inhibition of the agonist-induced response. The sensitizing actions of galanthamine, 5-hydroxytryptamine, and related compounds, at submicromolar concentrations, may reflect the existence of cross-talk between adjacent neuroreceptors and synapses in the central nervous system and thus suggests the formation of transiently active chemical networks in the vertebrate brain.
This article has been cited by other articles:
|
|
 |
|
  T.-Y. Wu, C. M. Smith, S. M. Sine, and M. M. Levandoski Morantel Allosterically Enhances Channel Gating of Neuronal Nicotinic Acetylcholine {alpha}3{beta}2 Receptors Mol. Pharmacol., August 1, 2008; 74(2): 466 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorrio, M. Sobrado, E. Arias, J. M. Roda, A. G. Garcia, and M. G. Lopez Galantamine Postischemia Provides Neuroprotection and Memory Recovery against Transient Global Cerebral Ischemia in Gerbils J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 591 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bandyopadhyay, B. Sutor, and J. J. Hablitz Endogenous Acetylcholine Enhances Synchronized Interneuron Activity in Rat Neocortex J Neurophysiol, March 1, 2006; 95(3): 1908 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Arias, S. Gallego-Sandin, M. Villarroya, A. G. Garcia, and M. G. Lopez Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1346 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Moriguchi, X. Zhao, W. Marszalec, J. Z. Yeh, and T. Narahashi Modulation of N-Methyl-D-aspartate Receptors by Donepezil in Rat Cortical Neurons J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 125 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Akk, L. S Milescu, and M. Heckmann Activation of heteroliganded mouse muscle nicotinic receptors J. Physiol., April 15, 2005; 564(2): 359 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Lyketsos, W. E. Reichman, P. Kershaw, and Y. Zhu Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease Am J Geriatr Psychiatry, October 1, 2004; 12(5): 473 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Moriguchi, W. Marszalec, X. Zhao, J. Z. Yeh, and T. Narahashi Mechanism of Action of Galantamine on N-Methyl-D-Aspartate Receptors in Rat Cortical Neurons J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 933 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Weible, M. M. Oh, G. Lee, and J. F. Disterhoft Galantamine Facilitates Acquisition of Hippocampus-Dependent Trace Eyeblink Conditioning in Aged Rabbits Learn. Mem., January 1, 2004; 11(1): 108 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Dajas-Bailador, K. Heimala, and S. Wonnacott The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+ Signals and Neurotransmitter Release. Mol. Pharmacol., November 1, 2003; 64(5): 1217 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Moriguchi, W. Marszalec, X. Zhao, J. Z. Yeh, and T. Narahashi Potentiation of N-Methyl-D-aspartate-Induced Currents by the Nootropic Drug Nefiracetam in Rat Cortical Neurons J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Samochocki, A. Hoffle, A. Fehrenbacher, R. Jostock, J. Ludwig, C. Christner, M. Radina, M. Zerlin, C. Ullmer, E. F. R. Pereira, et al. Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1024 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Piotrovsky, A. Van Peer, N. Van Osselaer, M. Armstrong, and J. Aerssens Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations J. Clin. Pharmacol., May 1, 2003; 43(5): 514 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Conroy, Q.-S. Liu, Q. Nai, J. F. Margiotta, and D. K. Berg Potentiation of alpha 7-Containing Nicotinic Acetylcholine Receptors by Select Albumins Mol. Pharmacol., February 1, 2003; 63(2): 419 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Capsoni, S. Giannotta, and A. Cattaneo Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice PNAS, September 17, 2002; 99(19): 12432 - 12437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Santos, M. Alkondon, E. F. R. Pereira, Y. Aracava, H. M. Eisenberg, A. Maelicke, and E. X. Albuquerque The Nicotinic Allosteric Potentiating Ligand Galantamine Facilitates Synaptic Transmission in the Mammalian Central Nervous System Mol. Pharmacol., May 1, 2002; 61(5): 1222 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Machu, M. E. Hamilton, T. F. Frye, C. L. Shanklin, M. C. Harris, H. Sun, T. E. Tenner Jr., F. S. Soti, and W. R. Kem Benzylidene Analogs of Anabaseine Display Partial Agonist and Antagonist Properties at the Mouse 5-Hydroxytryptamine3A Receptor J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1112 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Rockwood, J Mintzer, L Truyen, T Wessel, and D Wilkinson Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial J. Neurol. Neurosurg. Psychiatry, November 1, 2001; 71(5): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hodgkiss and J. S. Kelly Effect of FK960, a Putative Cognitive Enhancer, on Synaptic Transmission in CA1 Neurons of Rat Hippocampus J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 620 - 628. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Hsiao, D. Dweck, and C. W. Luetje Subunit-Dependent Modulation of Neuronal Nicotinic Receptors by Zinc J. Neurosci., March 15, 2001; 21(6): 1848 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Raskind, E. R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension Neurology, June 27, 2000; 54(12): 2261 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Tariot, P. R. Solomon, J. C. Morris, P. Kershaw, S. Lilienfeld, and C. Ding A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology, June 27, 2000; 54(12): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galli, L. D. Jayanthi, I. S. Ramsey, J. W. Miller, R. T. Fremeau Jr, and L. J. DeFelice L-Proline and L-Pipecolate Induce Enkephalin-Sensitive Currents in Human Embryonic Kidney 293 Cells Transfected with the High-Affinity Mammalian Brain L-Proline Transporter J. Neurosci., August 1, 1999; 19(15): 6290 - 6297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lazareno, P. Gharagozloo, D. Kuonen, A. Popham, and N. J. M. Birdsall Subtype-Selective Positive Cooperative Interactions between Brucine Analogues and Acetylcholine at Muscarinic Receptors: Radioligand Binding Studies Mol. Pharmacol., March 1, 1998; 53(3): 573 - 589. [Abstract] [Full Text]
|
|
|
|
|
|
R. Zwart and H. P. M. Vijverberg Potentiation and Inhibition of Neuronal Nicotinic Receptors by Atropine: Competitive and Noncompetitive Effects Mol. Pharmacol., November 1, 1997; 52(5): 886 - 895. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Damaj, G. S. Patrick, K. R. Creasy, and B. R. Martin Pharmacology of Lobeline, A Nicotinic Receptor Ligand J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 410 - 419. [Abstract] [Full Text]
|
|
|
|
|
|
E. X. Albuquerque, M. Alkondon, E. F. R. Pereira, N. G. Castro, A. Schrattenholz, C. T. F. Barbosa, R. Bonfante-Cabarcas, Y. Aracava, H. M. Eisenberg, and A. Maelicke Properties of Neuronal Nicotinic Acetylcholine Receptors: Pharmacological Characterization and Modulation of Synaptic Function, J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1117 - 1136. [Full Text]
|
|
|
|
 |
|
 H. Kleinert, C. Euchenhofer, I. Ihrig-Biedert, and U. Förstermann In Murine 3T3 Fibroblasts, Different Second Messenger Pathways Resulting in the Induction of NO Synthase II (iNOS) Converge in the Activation of Transcription Factor NF-kappaB J. Biol. Chem., March 15, 1996; 271(11): 6039 - 6044. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
